Biocept, Inc. (BIOCQ)

Market Cap	263.00
Revenue (ttm)	1.36M
Net Income (ttm)	-30.61M
Shares Out	2.63M
EPS (ttm)	-44.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,010
Average Volume	472
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	-35.60
RSI	44.04
Earnings Date	n/a

About Endeavor Group Holdings

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 50
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOCQ

Financial Performance

In 2022, Biocept's revenue was $25.86 million, a decrease of -57.78% compared to the previous year's $61.25 million. Losses were -$32.09 million, 1036.2% more than in 2021.